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Context: 
Low birth weight is associated with adverse metabolic outcome in adulthood. Exposure to 
glucocorticoid (GC) excess in utero is associated with decreased birth weight, but the prospective 
longitudinal relationship between GC metabolism and growth has not been examined. 
Objective: 
We have hypothesized that changes in GC metabolism leading to increased availability may impair 
growth. 
Design: 
This was a prospective, longitudinal study with clinical measurements and 24-hour urinary steroid 
metabolite analysis at 1, 4, 12, 26, and 52 weeks after delivery in mothers and their babies. 
Setting: 
The study was conducted with observations and samples collected in the volunteers' own homes. 
Participants: 
Healthy mothers and newborn babies/infants participated in the study. 
Interventions: 
There were no interventions. 
Main outcome measures: 
Urinary steroid metabolite excretion quantified by gas chromatography/mass spectroscopy across the 
first year of life in relation to change in weight was measured. 
Results: 
The total production of the GC metabolites quantified increased across the first year of life. Markers of 
11β-hydroxysteroid dehydrogenase type 1 activity increased from the age of 3 months as did those of 
5α-reductase activity. After correcting for confounding variables, low markers of 11β-hydroxysteroid 
dehydrogenase type 2 activity was associated with reduced absolute weight and decreased weight 
gain over the first year of life. In the mothers, 5α-reductase activity was low at birth and progressively 
increased to normal over the first 6 months postpartum. 
Conclusions: 
Increased GC exposure as a consequence of reduced 11β-hydroxysteroid dehydrogenase type 2 
activity is likely to be a critical determinant of growth in early life. This not only highlights the central 
role of GCs and their metabolism, but also emphasizes the need for detailed longitudinal analyses. 
 
 
There is a wealth of epidemiological evidence to support the hypothesis that low-birth-weight infants 
are predisposed to metabolic disease in adult life (1). Despite this, and faced with the global epidemic 
of obesity, diabetes mellitus, and metabolic disease, identification of the mechanisms underpinning 
this observation have remained elusive. The adrenal gland is responsible for the coordinated and 
highly regulated secretion of glucocorticoids (GCs), mineralocorticoids, and androgens, including 
dehydroepiandrosterone. Changing patterns of corticosteroid secretion and metabolism have been 
described in many common conditions including obesity and insulin resistance in children and adults 
(2–4). In utero, exposure to exogenous GCs at high doses, although often clinically indicated, can also 
have detrimental effects, including transient hyperinsulinemia in neonates (5), impaired vascular 
function, and reduced pancreatic β-cell function later in life (6). In rodent models, GC exposure 
decreases birth weight as well as inducing dysglycemia and insulin resistance in the offspring (7, 8), 
potentially delaying pubertal development (8). 
 
The regulation of GC action is complex and not simply determined by circulating concentrations. At a 
prereceptor level, the isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD) are able to 
interconvert inactive cortisone and active cortisol. 11β-HSD type 1 (11β-HSD1) is expressed in liver, 
adipose tissue, muscle, and bone and regenerates cortisol from cortisone. In contrast, 11β-HSD type 
2 (11β-HSD2) is expressed in mineralocorticoid target tissues, including kidney and large bowel, in 
which it inactivates cortisol to cortisone and thereby ameliorates the action of cortisol to bind and 
activate the mineralocorticoid receptor, for which it shares a similar affinity to aldosterone. Genetic 
defects in 11β-HSD2 cause the syndrome of apparent mineralocorticoid excess (AME), which can 
present with uncontrolled hypertension and life-threatening hypokalemia in childhood and in addition 
is associated with low birth weight (9). Furthermore, decreased placental 11β-HSD2 gene expression 
has been implicated in the pathogenesis of intrauterine growth restriction (10). 
 
In parallel, the A-ring reductases, 5α-reductase types 1 and 2, (5αR1 and 5αR2) and 5β-reductase 
convert cortisol and cortisone to their dihydrometabolites, and these are subsequently converted to 
tetrahydrometabolites through the action of 3α-hydroxysteroid dehydrogenase. In addition, 5α-
reductase (largely 5αR2) is crucial for converting T to the more potent androgen, dihydrotestosterone, 
and genetic defects in 5αR2 lead to 46XY disorder of sexual differentiation; genetic defects in 5αR1 
have not been described. The role of the A-ring reductases in neonatal and infant growth and 
development has not been explored. 
 
In this study, we have tested the hypothesis that increased cortisol exposure through increased 11β-
HSD1, decreased 11β-HSD2 or decreased A-ring reductase activity, individually or in combination, 
contributes to changes in growth and development across the first year of life. To answer this 
question, we designed a prospective longitudinal study to characterize corticosteroid metabolite 
profiles in a cohort of healthy babies and their mothers across the first year of life. 
 
 
 
 
 
 
Materials and Methods 
Clinical Protocol 
The clinical protocol received full ethical approval from Birmingham East, North, and Solihull Research 
Ethics Committee, United Kingdom (reference number 10/H1206/67). Research and development 
approval was granted by Birmingham Women's National Health Service Foundation Trust (reference 
number 10/BWH/NO95). 
 
Recruitment took place on low-risk maternity units in Birmingham, West Midlands, United Kingdom, 
and women without complications during pregnancy and labor were identified and approached; fully 
informed written consent was obtained. Mothers and infants were visited at 1 week, 1 month, 3 
months, 6 months, and 12 months postpartum. At all time points apart from 3 months, maternal and 
infant weight and infant length were measured. Infants were weighed without clothes. Weight was 
converted to a SD score (SDS), which adjusts measurements for age and gender (Child Growth 
Foundation, 1996). Infant length was measured to the nearest 0.5 cm using a Seca 210 mobile 
measuring mat. Mothers were weighed wearing light indoor clothing without shoes. Maternal height 
was measured at 1 week postpartum using a stadiometer. 
 
During the 1-week home visit, mothers reported their pregnancy medical history and completed 
questionnaires ascertaining demographic information. At each time point, mothers provided a single 
maternal urine sample and a 24-hour collection of wet diapers to determine androgen and cortisol 
metabolites (see below). 
 
Extraction of urine from diapers 
Diapers in the 24-hour collections were counted and weighed. The wet material was removed and 
placed in a beaker and a measured volume of 4% saline solution was added (∼1 mL/g of gel). The 
samples were squeezed by hand for 5 minutes and then left at 4°C overnight to equilibrate. The 
diaper extract was then put through a potato ricer containing a square of nylon gauze and the liquid 
collected and filtered through glass wool to remove residual particles of gel. The samples were then 
analyzed as described below. The total volume of the collection was calculated from the equation: 
total volume (milliliters) = [weight of wet diapers (grams) − expected total weight of dry diapers 
(grams)] + total amount of saline added. Prior development established that disposable diapers 
consist of cellulose fluff containing supersorb granules (polyacrylate resin) and that there were no 
material differences between the major brands, eg, Pampers (Proctor and Gamble) and Huggies 
(Kimberly-Clark). Pure samples of the resin were shown not to selectively retain steroids. The saline 
concentration was established at 4% to minimize gel swelling. Experiments involving dripping urine 
onto new diapers established that steroid recovery was close to 100%. The dry weight of a given 
diaper type was established by weighing 20 examples and obtaining the mean. Dry diaper weights 
were small in relation to the urine weight and showed low variation. Therefore, possible errors in the 
calculated urine volume (due to an inaccurate estimation of dry diaper weight) were considered to be 
negligible. 
 
Urinary steroid analysis 
Urinary androgen and corticosteroid metabolite analysis was performed by gas chromatography/mass 
spectroscopy as described previously (4, 11). Briefly, free and conjugated steroids were extracted 
from urine by solid-phase extraction. Steroids were enzymatically released from conjugation and 
reextracted. An internal standard (stigmasterol) was added prior to derivitization to form methyloxime-
trimethylsilyethers. The final derivative was dissolved in cyclohexane, which was transferred to a gas 
chromatography/mass spectroscopy autosampler vial. The samples were run on an Agilent 5973 
instrument in selected ion monitoring mode. It should be stated that only a few classical cortisol (F) 
metabolites were measured, dependent on their availability as authentic compounds necessary for 
instrument calibration. Newborns in particular have important metabolites that were not included, 
especially 1β- and 6α-hydroxylated metabolites of tetrahydrocortisone and the cortolones (12). In this 
document, use of the term, total F metabolites (see definition below), means the total of measured 
metabolites, not the complete excretion of all metabolites. We have estimated that the percentage of 
measured metabolites as compared with the complete excretion of all metabolites is approximately 
49% at 1 week of age, 60% at 1 month, 74% at 3 months, 85% at 6 months, and 91% at 12 months of 
age. 
 
Interpretation of totals and indices of urinary steroid excretion 
The sum of total cortisol metabolites [tetrahydrocortisol (THF), tetrahydrocortisone (THE), 5α-THF, α-
cortolone, cortisone (E), F, β-cortolone, β-cortol, α-cortol] provides a reflection of cortisol secretion 
rate (total F metabolites). The ratio of tetrahydrometabolites of cortisol (THF + 5αTHF) to those of 
cortisone (THE) provides a reflection of 11β-HSD1 activity when considered with the ratio of urinary F 
to E, which more accurately reflects renal 11β-HSD2 activity (higher F to E ratios indicative of 
decreased 11β-HSD2 activity). Urinary free F and E, which provide the most accurate assessment of 
11β-HSD2 activity were not measured (11,13), although our own in-house analysis has shown a good 
correlation between hydrolyzed (free measurements) and nonhydrolyzed samples (cortisol r = 0.80, 
cortisone r = 0.71). In addition, the ratio of cortols to cortolones reflects 11β-HSD1 activity. Evidence 
to support the interpretation of these ratios is provided from studies using selective 11β-HSD1 
inhibitors and patients with mutations causing functional defects in 11β-HSD1 (14, 15). The activities 
of 5α- and 5β-reductases can be inferred from measuring the ratio of 5αTHF to THF and 
androsterone (An) to etiocholanolone (Et). 
 
Creatinine assay 
Creatinine was measured using a QuantiChrom creatinine assay kit (BioAssay Systems), which is 
designed to measure creatinine directly in biological samples without any pretreatment. The assay is 
based on a kinetic Jaffe reaction, which uses picrate that forms a red-colored complex with creatinine. 
The intensity of the color, measured at 510 nm, is directly proportional to creatinine concentration in 
the sample. 
 
Statistical approach 
Data are presented as median and interquartile range (IQR) unless otherwise stated. Statistical 
analysis was undertaken using the R software language and the mixed-effects models were 
calculated using the LME4 package (http://cran.r-project.org/package=lme4); the Markov Chain Monte 
Carlo estimates of the random effects parameters and confidence intervals were calculated using the 
languageR package. Data were modeled using a mixed fixed and a random factor linear effects 
model, which used random effects to model those sources of variation attributable to the design of the 
study. In this model, time of measurement and type of steroid were treated as random factors within a 
random intercept model. Because each of the steroid levels was measured on a different metric, 
these data were standardized to z-scores prior to the subsequent analysis. For infant samples, the 
additional effect of gender was incorporated in to the statistical models to determine the two-way 
interactions (eg, gendersteroid and gendertime) and three-way interactions effect (eg, 
gendertimesteroid). Detailed statistical methods and model descriptions are presented in 
Supplemental Tables 1–4. 
 
Results 
Fifty-nine mothers [mean age 29 ± 5 y, mean body mass index (BMI) 26.9 ± 3.9 kg/m2] and their 
infants [36 males, 23 females; mean birth weight 3.51 kg (SD 0.36)] were recruited from low-risk 
maternity units after delivery (all provided informed written consent). Thirty-four percent (20 of 59) 
were in their first pregnancy, 19% (11 of 59) continued to smoke during pregnancy, and 24% (14 of 
59) consumed alcohol, although all within recommended limits. None had any significant past medical 
history and none were taking any regular medication. Any mother with gestational diabetes, 
preeclampsia, or pregnancy-induced hypertension was excluded from the study. Infants born 
prematurely (prior to 36 wk gestation) or small for gestational age were not eligible for this study. All 
births were spontaneous normal vaginal deliveries without compilations. Birth weight (absolute and 
SDS) and growth across the first year of life of the neonatal/infant cohort are presented in Table 1. 
Steroid ratios from one infant were excluded from the analysis because the ratios reflecting the 5α-
reductase activity were more than 2 SD above the mean. 
 
Table 1.Changes in Weight and Length Over the First Year of Life in a Cohort of Healthy Babies 
Sex 
Birth 
 
1 Week 
 
1 Month 
 
6 Months 
 
12 Months 
 
Mal
e 
Femal
e 
Mal
e 
Femal
e 
Mal
e 
Femal
e 
Mal
e 
Femal
e 
Mal
e 
Femal
e 
n 37 22 29 11 29 14 24 13 29 20 
Age at 
visit, 
wks   
1.3 ± 
0.3 
1.3 ± 
0.4 
4.8 
± 
0.6 
4.7 ± 
0.5 
26.7 
± 
1.3 
26.9 ± 
0.7 
53.1 
± 1.9 
53.3 ± 
1.8 
Weight
, kg 
3.54 
± 
0.39 
3.46 ± 
0.30 
3.56 
± 
0.38 
3.41 ± 
0.32 
4.63 
± 
0.47 
4.28 ± 
0.39 
8.28 
± 
1.11 
7.63 ± 
0.81 
10.4
1 ± 
1.36 
9.37 ± 
1.01 
Weight 
SDS 
0.13 
± 
0.77 
0.38 ± 
0.71 
−0.5
5 ± 
0.75 
−0.53 
± 0.64 
0.05 
± 
0.78 
−0.05 
± 0.71 
0.13 
± 
1.25 
0.03 ± 
0.99 
0.15 
± 
1.27 
−0.23 
± 1.07 
SDS 
weight 
gain 1 
to 12 
mo 
        
0.13 
± 
1.27 
−0.30 
± 1.13 
Length
, cm 
52.2 
± 
2.7 
51.9 ± 
2.3 
53.6 
± 2.2 
53.1 ± 
1.7 
58.4 
± 
2.5 
56.6 ± 
1.6 
73.1 
± 
2.9 
70.0 ± 
2.4 
79.4 
± 2.7 
77.2 ± 
3.2 
Length 
SDS 
0.74 
± 
1.25 
1.12 ± 
1.47 
0.70 
± 
1.07 
0.98 ± 
0.85 
1.59 
± 
1.17 
1.34 ± 
0.77 
2.36 
± 
1.26 
1.81 ± 
1.08 
1.42 
± 
1.13 
1.18 ± 
1.33 
 
Data presented are mean ± SD. Although urine samples were collected at 3 months, clinical 
parameters were not measured. 
 
Changes in corticosteroid metabolism across the first year of life 
There were no significant differences in steroid metabolites or their ratios between boys and girls, and 
therefore, the analysis against time of the complete cohort is presented. The absolute data divided 
according to gender are presented in Supplemental Table 5. Steroid excretion data are summarized 
in Figure 1 and Table 2. 
 
Figure 1. Neonatal and infant cortisol metabolite production (micrograms per 24 h) (A) and urinary 
steroid metabolite ratios (B–F) across the first year of life. The F to E ratio (B) reflects 11β-HSD2 
activity; 5αTHF+THF to THE (C) and cortol to cortolone ratios (D) ratios reflect 11β-HSD1 activity and 
5αTHF to THF (E) and An to Et (F) ratios reflect 5α-reductase activity. DHEA, 
dehydroepiandrosterone. There was no impact of gender on the patterns of change in steroid 
hormone metabolites with time, and P values reflect the interaction of individual steroid metabolites or 
ratios (boys and girls combined) with time. 
 
 
Table 2.Longitudinal 24-Hour Urinary Steroid Metabolite Analysis in a Cohort of Healthy Babies 
Across the First Year of Life 
 
1 
Week 
(n = 
50) 
1 
Month 
(n = 
56) 
3 
Months 
(n = 
55) 
6 
Months 
(n = 
49) 
12 
Months 
(n = 
47) 
Total F 
metabolites      
    
Median 280.7 539.8 767.9 970.6 999.4 
    IQR 273.1 405.0 602.2 639.3 852.9 
THF      
    
Median 1.50 2.35 15.1 51.6 87.7 
    IQR 1.93 2.47 12.5 48.3 94.9 
5α-THF      
    
Median 0.97 5.76 95.1 260.6 255.6 
    IQR 2.05 11.25 96.7 207.6 293.0 
THE      
    
Median 188.8 309.1 404.1 382.2 382.7 
    IQR 157.9 247.7 397.2 278.4 398.4 
Cortisol      
    
Median 10.5 11.4 9.4 8.0 10.7 
    IQR 10.3 10.0 5.6 6.4 15.3 
Cortisone      
    
Median 17.7 26.4 20.6 18.2 16.6 
    IQR 20.1 24.7 12.9 11.4 18.4 
α-Cortol      
    
Median 7.9 18.1 14.1 19.1 26.3 
    IQR 9.1 22.5 12.7 14.9 25.6 
β-Cortol      
    
Median 1.8 4.1 12.5 27.1 50.0 
    IQR 2.1 4.4 11.4 23.9 63.7 
 
      
 1 
Week 
(n = 
50) 
1 
Month 
(n = 
56) 
3 
Months 
(n = 
55) 
6 
Months 
(n = 
49) 
12 
Months 
(n = 
47) 
α-Cortolone 
    
Median 7.8 25.8 40.3 55.3 71.3 
    IQR 13.4 26.1 27.7 30.7 69.6 
β-Cortolone      
    
Median 49.9 118.5 126.5 93.5 82.2 
    IQR 64.7 128.2 125.4 75.5 97.1 
An      
    
Median 2.1 4.4 4.1 3.6 3.8 
    IQR 2.0 5.3 4.3 3.6 7.3 
Et      
    
Median 0.73 0.67 0.55 0.62 1.75 
    IQR 0.69 0.71 0.53 0.49 2.50 
DHEA      
    
Median 2.83 2.82 1.47 0.85 0.91 
    IQR 3.04 3.79 1.69 1.02 1.60 
16α-OH-
DHEA      
    
Median 191.6 294.0 57.9 14.3 5.1 
    IQR 437.7 546.1 65.2 20.4 11.2 
F to E ratio      
    
Median 0.53 0.38 0.47 0.50 0.70 
    IQR 0.31 0.16 0.13 0.19 0.34 
(THF+5αTHF) 
to THE ratio      
    
Median 0.02 0.03 0.35 0.91 0.95 
    IQR 0.01 0.03 0.29 0.48 0.45 
Cortol to 
cortolone ratio      
    0.16 0.16 0.17 0.34 0.53 
 1 
Week 
(n = 
50) 
1 
Month 
(n = 
56) 
3 
Months 
(n = 
55) 
6 
Months 
(n = 
49) 
12 
Months 
(n = 
47) 
Median 
    IQR 0.10 0.17 0.16 0.13 0.20 
5αTHF to 
THF ratio      
    
Median 0.86 3.33 6.71 4.92 2.71 
    IQR 0.70 2.56 3.47 3.27 1.36 
An to Et ratio      
    
Median 2.74 6.25 7.53 5.51 2.63 
    IQR 2.70 5.38 6.32 2.98 1.58 
 
Abbreviations: DHEA, dehydroepiandrosterone; OH-DHEA, hydroxydehydroepiandrosterone. Data 
presented are median with the IQR. Individual steroid metabolites are quoted in micrograms per 24 
hours. Statistical analysis was performed using Wald type II χ2tests of deviation for the time by steroid 
interaction. There was no impact of sex on the statistical modeling. 
 
Total cortisol metabolites increased across the first year of life (P < .00001) (Table 2 andFigure 1). 
However, this must be interpreted with caution because the proportion of quantified metabolites 
increased with time (see Materials and Methods). 11β-HSD1 activity, reflected by the 5αTHF+THF to 
THE and cortol to cortolone ratios, was almost undetectable until 3 months of age and then increased 
dramatically between 3 and 6 months, with stable values at 12 months (P < .00001) (Table 
2 and Figure 1). 5α-Reductase activity, as estimated by the 5αTHF to THF and An to Et ratios, was 
also low at birth, rising significantly to a peak at 3 months of age and then showing a decrease at 6 
months with a further decrease at 12 months of age (P < .00001) (Table 2 and Figure 1). Both 5α- and 
5β-reduced metabolites of cortisol (5α-THF and THF, respectively) increased progressively, but the 
excretion of the 5α-epimer was 5-fold higher (Table 2 and Figure 1). The F to E ratio also increased 
with time, indicative of decreasing 11β-HSD2 activity, although the change was less marked than that 
observed for 11β-HSD1 and 5α-reductase activity (P < .0005) (Table 2 and Figure 1). 
 
Changes in maternal corticosteroid metabolite analysis postpartum 
 
Spot urine analysis rather than 24-hour samples were analyzed and absolute corticosteroid 
concentrations were corrected per gram of urinary creatinine to allow for the assessment of absolute 
production rates. Total F metabolite production and urinary F to E ratio did not change significantly 
over the first 12 postpartum months. Although the cortol to cortolone ratio was weakly associated with 
time (P = .047, Table 3), there was no relationship with the 5αTHF+THF to THE, suggesting that 11β-
HSD1 activity did not change significantly. 
 
 
 
 
 Table 3.Longitudinal Changes in Urinary Steroid Metabolite Analysis in a Cohort of Healthy Mothers 
in the First Postpartum Year 
 
1 
Week 
(n = 
45) 
1 
Month 
(n = 
53) 
3 
Months 
(n = 
45) 
6 
Months 
(n = 
46) 
12 
Months 
(n = 
41) 
Total F 
metabolites      
    
Median 6711 7476 6661 7214 6838 
    IQR 2786 2552 3325 3015 2855 
THF      
    
Median 1580 1480 1095 1229 1003 
    IQR 722 662 609 558 379 
5α-THF      
    
Median 265 551 793 996 831 
    IQR 197 451 621 781 666 
THE      
    
Median 2326 2764 2443 2394 2363 
    IQR 1217 1026 174 1425 1386 
Cortisol      
    
Median 84.0 48.0 44.0 50.5 62.0 
    IQR 64.5 32.5 35.0 32.0 48.5 
Cortisone      
    
Median 108.0 77.0 69.0 87.0 120.0 
    IQR 76.0 40.0 42.0 43.8 92.5 
α-Cortol      
    
Median 326.0 247.0 211.0 277.0 237.0 
    IQR 179.0 146.0 92.0 110.3 118.5 
β-Cortol      
    
Median 440.0 397.0 330.00 385.5 339.0 
    IQR 258.5 225.0 206.5 224.5 163.0 
 1 
Week 
(n = 
45) 
1 
Month 
(n = 
53) 
3 
Months 
(n = 
45) 
6 
Months 
(n = 
46) 
12 
Months 
(n = 
41) 
α-Cortolone      
    
Median 1205 1112 856 1036 1072 
    IQR 569 663 523 454 552 
β-Cortolone      
    
Median 385.0 469.0 436.0 500.0 482.0 
    IQR 196.0 255.5 241.0 264.8 223.0 
An      
    
Median 583.0 679.0 1148.0 1326.0 1565.0 
    IQR 560.5 852.0 921.0 1092.8 1119.0 
Et      
    
Median 1237 1261 1262 1079 1152 
    IQR 939 969 933 698 900 
DHEA      
    
Median 146.0 88.0 125.0 104.0 159.0 
    IQR 270.0 124.0 210.5 227.3 503.0 
16α-OH-
DHEA      
    
Median 244.0 212.0 246.0 240.0 400.0 
    IQR 480.5 279.5 378.0 298.3 645.0 
F to E ratio      
    
Median 0.80 0.62 0.63 0.63 0.63 
    IQR 0.33 0.30 0.24 0.28 0.33 
(THF+5αTHF) 
to THE ratio      
    
Median 0.86 0.79 0.90 1.02 0.77 
    IQR 0.32 0.26 0.33 0.36 0.22 
Cortol to 
cortolone ratio      
    0.47 0.40 0.45 0.48 0.39 
 1 
Week 
(n = 
45) 
1 
Month 
(n = 
53) 
3 
Months 
(n = 
45) 
6 
Months 
(n = 
46) 
12 
Months 
(n = 
41) 
Median 
    IQR 0.22 0.15 0.17 0.13 0.11 
5αTHF to 
THF ratio      
    
Median 0.18 0.39 0.75 0.87 0.89 
    IQR 0.12 0.32 0.51 0.82 0.53 
An to Et ratio      
    
Median 0.45 0.57 0.99 1.15 1.20 
    IQR 0.24 0.47 0.95 0.88 0.59 
 
Data presented are median with the IQR. Urinary corticosteroid production is expressed per grams of 
urinary creatinine. DHEA, dehydroepiandrosterone; OH-DHEA, hydroxydehydroepiandrosterone. 
Statistical analysis was performed using Wald type II χ2tests of deviation for the time by steroid 
interaction. 
 
However, 5α-, relative to 5β-reductase activity, reflected in the 5αTHF to THF and An to Et ratios was 
low in the immediate postpartum period and increased over the initial 3 months and then stabilized 
(both P < .00001, Table 3). By 12 months, values were similar to those seen in a reference cohort of 
women (data not shown). Changes in the 5αTHF to THF and An to Et ratios were driven by lower 
absolute concentrations of both 5αTHF (P < .0001) and An (P < .05), indicative of changes specifically 
in 5α- rather than 5β-reductase activity. 
 
The relationship between maternal and neonatal/infant corticosteroid metabolism 
 
Partial correlation analysis was performed, adjusting for confounding variables (including infant 
gender and weight SDS, maternal age, BMI, and smoking) to examine any potential relationships 
between maternal and neonatal/infant urinary steroid metabolites; no significant relationships at any 
time point were identified (data not shown). 
 
Corticosteroid metabolism as a regulator of neonatal/infant growth 
 
Partial correlation analysis was performed adjusting for confounding variables including infant gender, 
maternal age and BMI, smoking during pregnancy and the age of introduction of solids. Elevation of 
the urinary F to E ratio at week 1, consistent with impaired 11β-HSD2 activity, was inversely related to 
weight at week 1 (R2 = −0.46, P < .01). Furthermore, at 12 months of age, there was a negative 
relationship between F to E ratio and 12-month weight SDS (R2 = −0.40, P < .05) as well as weight 
gain SDS over the first 12 months of life (R2 = −0.51, P < .01). In addition, length SDS at 12 months 
was also negatively associated with F to E ratio (R2 = −0.35, P < .05), suggesting that impaired 11β-
HSD2 activity with consequent increased cortisol availability may limit growth (Table 4). 
 
 
 
Table 4.Partial Correlation (2-Tailed) Analysis Examining the Relationship Between Neonatal/Infant 
Corticosteroid Metabolite Ratios and Weight Across the First Year of Life With Adjustment for Infant 
Gender, Maternal Age and BMI, Smoking During Pregnancy and the Age of Introduction of Solids (N = 
31) 
Urinary Steroid 
Metabolite Ratio 
1-
Week 
Weight 
SDS 
1-
Month 
Weight 
SDS 
6-
Month 
Weight 
SDS 
12-
Month 
Weight 
SDS 
1- to 
12-
Month 
SDS 
Weight 
Gain 
Concurrent F/E −0.46a −0.21 −0.08 −0.40b −0.51a 
Concurrent 
THF+5αTHF/THE 0.09 0.03 −0.15 −0.09 −0.11 
Concurrent 
5αTHF/THF −0.05 −0.00 −0.06 0.05 0.09 
Concurrent Total 
F Metabolites 0.20 0.19 0.04 0.03 −0.09 
aP< .01; 
bP< .05. 
 
In contrast, there was no relationship between urinary steroid metabolite ratios reflecting 11β-HSD1 
activity, 5α-reductase activity, or total GC metabolite production rate with absolute weight at the time 
of analysis or weight gain across the duration of the study (Table 4). However, after correcting for 
confounding variables, increased duration of breastfeeding was associated with higher 5α-reductase 
activity at 6 and 12 months and increased 11β-HSD1 activity at 12 months (Supplemental Table 6). 
There were no relationships between urinary steroid metabolite ratios and smoking status (data not 
shown). 
 
Discussion 
In this study, we have performed the first longitudinal characterization of corticosteroid metabolism 
across the first year of life. We have highlighted dramatic changes in the pattern of corticosteroid 
metabolite production and identified a potential role for GC metabolism, notably 11β-HSD2, to 
regulate growth and weight gain. 
 
Both GC receptor and mineralocorticoid receptors (MR) are expressed in most tissues throughout 
fetal development (16, 17) and are critical to development; GC receptor knockout mice die shortly 
after birth (18). Clinical treatment with exogenous GC is indicated to promote organs, notably lung 
maturation (19), but in both human and rodent models, GC excess is associated with decreased birth 
weight (20–22). 
 
We have shown that decreased 11β-HSD2 activity was associated with decreased weight gain across 
the first year of life as well as decreased length at 12 months, and it is possible that this is a reflection 
of decreased GC clearance. 11β-HSD2 is highly expressed in the human placenta, in which it serves 
to protect the developing fetus from high levels of active GCs. Although expressed in the fetus (16), a 
recent study has suggested that renal neonatal 11β-HSD2 activity is low in comparison with placental 
activity (23). In our study, the F to E ratio increased across the first year of life (suggesting decreasing 
11β-HSD2 activity), and at 12 months, the levels were similar to those seen in the maternal cohort 
and to those observed in an adult control population (4); it is possible that this reflects changing 
patterns of enzyme expression. In our cohort, F to E ratios were, if anything, lower than those 
measured in the maternal samples at week 1, and this would tend to suggest increased (rather than 
decreased) 11β-HSD2 activity in the first weeks after birth. The discrepancies in data may reflect 
differences in methodology, but perhaps most importantly, the use of 24-hour samples rather than 
spot urines. Unfortunately, we did not have access to serum or placental samples as part of this 
study. In rodent models, the levels of 11β-HSD2 correlate with fetal size (24), and there is evidence to 
support this in humans in whom the mRNA levels and the activity of 11β-HSD2 are associated with 
lower birth weight (25), although this is not a consistent finding in all studies (26). However, 
pharmacological inhibition of 11β-HSD2 with carbenoxolone and the genetic manipulation of 11β-
HSD2 activity decrease birth weight (27, 28). 
 
More than 50 different mutations in HSD11B2, the gene encoding 11β-HSD2, that cause AME have 
now been described (29). Cortisol and aldosterone share a similar affinity for the MR, and therefore, in 
the absence of 11β-HSD2, cortisol (which circulates at levels > 1000-fold that of aldosterone) will 
become the predominant ligand for the MR, leading to hypertension and hypokalemia. Several cases 
of AME presenting in the first year of life have been described and are associated with low birth 
weight, and this is believed to be due, at least in part, to increased fetal exposure to GCs (30). In our 
study, no child had urinary steroid metabolite ratios that would suggest undiagnosed AME, and it is 
possible therefore that a functional defect in 11β-HSD2 is responsible for the observations in this 
study. Although the absence of 11β-HSD2 activity causing low weight gain is clearly detrimental, 
excessive weight gain across the first year of life is also associated with adverse outcomes in 
childhood (31). It is possible therefore that there is a balance of activity that is optimal for growth 
across the first year of life, and this would need to be tested in extended longitudinal studies across 
childhood. 
 
11β-HSD1 generates active GCs within key metabolic target tissues. In our study, activity remained 
low until 3 months of age and then gradually increased. This is likely to have a functional importance 
because case reports have been described in which neonates born with congenital adrenal 
hyperplasia fail to respond to inactive cortisone acetate (which requires 11β-HSD1 for activation to 
cortisol) (32). Urinary steroid metabolite assessment of 11β-HSD1 activity is believed to largely reflect 
hepatic activity. Data from preclinical studies and clinical trials of selective 11β-HSD1 inhibitors have 
demonstrated a role for 11β-HSD1 in the regulation of glucose and lipid metabolism (33, 34). It is 
plausible that the predisposition of neonates to develop hypoglycemia could arise as a result of a 
decreased gluconeogenesis, due to lack of ability to locally regenerate active glucocorticoids, 
although this hypothesis remains entirely untested. The lack of a relationship between 11β-HSD1 
activity and growth across the first year of life is perhaps to be expected. Lack of expression and 
activity in the first few months of life would suggest that the contribution that 11β-HSD1 makes to GC 
exposure over this time is limited. In addition, there is no evidence from rodent models that genetic 
deletion of 11β-HSD1 impairs growth and development in the early stages of life (35). 
 
5αR1 is expressed in the neonatal liver, and this continues throughout life. In the nongenital skin, 
expression persists up until 2–3 years of age and then decreases but increases again around the time 
of puberty (36); it is thought to be contributory to pubertal virilization in patients with 5αR2 deficiency. 
5αR2 is also expressed in the neonatal and adult liver. Expression remains in the nongenital skin for 
the first 2–3 years of life and then decreases, only persisting in the prostate, epididymis, seminal 
vesicles, and urogenital skin (37). Despite the evidence of a link between metabolic phenotype and 
5αR in adults (4, 38–40), we did not observe any relationship with growth in the first year. However, 
activity was low at birth increasing dramatically at 3 months with levels decreasing by 6 and 12 
months. Our longitudinal data are in agreement with published cross-sectional analyses that have 
shown a similar relationship with time (41). 
 
In addition to these direct actions of GCs, there is evidence that exposure to GC excess has a 
detrimental impact later in life though programming. In a variety of animal models, GC exposure 
during gestation can impact adult phenotype (42, 43). Blood pressure is increased and this may be 
driven by alterations in the pattern of corticosteroid receptor expression, changes in sympathetic 
innervation, and vascular reactivity (44, 45). Similarly, adult insulin sensitivity can also be altered by 
prenatal GC exposure, leading to altered glucose homeostasis (46) and may contribute to the 
development of conditions including nonalcoholic fatty liver disease (47) and impaired pancreatic β-
cell development (48). 
 
Prereceptor GC metabolism has also been implicated in the programming process. Dexamethasone 
treatment to pregnant rodents induces hypertension in adult offspring that is associated with 
decreased 11β-HSD2 expression in the distal nephron without any significant change in MR or 11β-
HSD1 expression (49). Although in this study we failed to demonstrate any relationship between 11β-
HSD1 activity and growth across the first 12 months of life, GC exposure during gestation in a primate 
model increases 11β-HSD1 expression in liver and adipose tissue later in life (50) and based on 
rodent models and clinical studies, this may contribute to the development of an adverse metabolic 
phenotype (51). 
 
The data in humans are less clear, with discrepancies in the published data as to the impact of GC 
administration in the first few years of life (52, 53). The impact later into adult life also remains 
controversial, with some studies showing a detrimental impact on blood pressure and insulin action 
(54, 55), but this is not a consistent finding across all studies (56). We have examined outcomes only 
in the first year of life, but tracking changes in metabolic and steroid metabolite phenotype as this 
cohort ages will prove highly informative. 
 
In conclusion, we have demonstrated a relationship between 11β-HSD2 activity and weight across the 
first year of life, suggesting that increased GC exposure through this mechanism may limit growth. 
Further studies are undoubtedly warranted, not only to see whether this longitudinal relationship is 
maintained later into childhood but also to understand its relevance in children who were small for 
gestational age or born after maternal preeclampsia and pregnancy-induced hypertension. 
Abbreviations: 
AME apparent mineralocorticoid excess 
An androsterone 
BMI body mass index 
E cortisone 
Et etiocholanolone 
F cortisol 
GC glucocorticoid 
11β-HSD 11β-hydroxysteroid dehydrogenase 
11β-HSD1 11β-HSD type 1 
11β-HSD2 11β-HSD type 2 
IQR interquartile range 
MR mineralocorticoid receptors 
5αR1 5α-reductase type 1 
5αR2 5α-reductase type 2 
SDS SD score 
THE tetrahydrocortisone 
THF tetrahydrocortisol. 
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